O-18 The evolution of screening and diagnostic testing for SARS CoV2 in Grenada
Author(s):
N Cudjoe , N Noel , P Fields , V Belmar-Matthew , B Sharma , E Chitan , T Khan , N Steele , S Charles , TP Noel, K Yearwood and CNL Macpherson
Year of Presentation:
2022
Objective: To provide an overview on the screening, diagnostic methods, sample collection and compare the cycle threshold values from RT-qPCR testing from March 2020 – January 2022 in Grenada.
Methods: Samples were collected through the SARSCoV-2 surveillance/ screening programmes at St. George’s University or through the Government of Grenada. Samples were collected via nasopharyngeal swabs or saliva collection devices and were tested via RT-qPCR or lateral flow antigen testing. Subsequent samples were taken the same day from individuals who tested positive on rapid antigen testing for RT-qPCR testing. The cycle threshold values were recorded for each positive sample identified through RT-qPCR testing.
Results: The first mandated screening session from August – September 2021, showed a positivity rate of 1.3% followed by no positive cases in the second mandated screening session in October 2021. The prevalence corresponded closely within the wider Grenadian community. Exposed individuals during the Omicron wave had a higher viral load in comparison to other infected individuals in the previous Alpha and Delta waves.
Conclusion: The developments in technology and increase in knowledge for the screening and diagnostic tools for SARS-CoV-2 continue to evolve. Screening and surveillance outcomes assist with public health decision making in a small island developing state.